| Prev Close | 182.50 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 99.91 / 187.45 |
Alexion Pharmaceuticals, Inc. (ALXN)
182.50
| Exchange | |
| Div & Yield | N.A. (N.A) |
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
Dump These 5 'Toxic Stocks' Before the New Year
Start 2017 on the right foot by selling your holdings in these five stocks.
Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Bullish and Bearish Reversals for the Week
Here's a window into what institutional investors may be doing and how to profit from that.
Rev's Forum: Don't Be Seduced by the Market's Dark Side
Too many turn bearish too quickly just because they can't find any entry points.
Trader's Daily Notebook: Gusher for Oil Stocks
Big move for biotechs isn't pleasant.
Here’s Why Shares of Biogen and Alexion Tanked On Tuesday
Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.
Trending Tickers: Z, VRX, BIIB, ALXN
U.S. indices are up as oil continues its climb past $50 a barrel.
U.S. Futures and World Markets Blindsided by Bank of Japan Decision
Crude prices were also falling following the BOJ's decision to keep its monetary policy unchanged.
Alexion Pharmaceuticals' Big Top Foreshadows Big Drop
The next potential support levels are the $120 and $100 areas from 2013.
Novice Trade: Illumina
ILMN's three-month at-the-money implied volatility is at about the median level.
Deluge of Deals Isn't About to Dry Up
Acquisitions cut into overabundance of companies.
3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Market Wrap: Yellen Delivers a Jolt
U.S. stocks fell for a second straight session.
Microsoft Lags Dow in Tech Selloff; Yellen Spooks Wall Street
Stocks pared losses, though remained in the red by close as markets weighed comments from Federal Reserve Chair Janet Yellen that equity valuations were possibly stretched.
Herbalife Beats Estimates; Stocks Open Slightly Higher as Crude Rallies
Herbalife (HLF) rallied after boosting full-year earnings forecasts as sales in China showed strength.
The 7 Pillars of Healthcare Strength
Here are healthcare stocks of all shares and sizes with strong charts.
Braving Biotech
Do you need to pick one name? Biotech has carried with it a lasting resiliency like few other sectors. Perhaps it is driven by optimism and hope. Perhaps it is driven by the fear of suffering or watching someone suffer from the very illnesses these ...
Those Sensitive Biotechs
They are prone to being whipsawed by news.
The Trader Daily
A few stocks that could break higher.
Why You Should Watch Fibonacci Extensions
As these examples illustrate, it's just good risk management.